Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SYRE · as of Sep 30, 2025
Ownership Breakdown
138
Institutional Holders
▲ 8 vs Q2
$1.08B
Total Inst. Value
▲ $125.05M vs Q2
60.40M
Shares Outstanding
freeFloat 87.04%
64.30M
13F Shares Held
▲ 673,991 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SYRE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 9.06M | 12.09% | 12.09% | $151.85B | Nov 13, 2025 | ▲ 7.1K |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 4.02M | 5.36% | 5.36% | $67.34B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 3.98M | 5.32% | 5.32% | $66.75B | Nov 12, 2025 | ▼ 24.6K |
RTW INVESTMENTS, LP pharmaceutical preparations | 3.62M | 4.83% | 4.83% | $60.70B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 3.20M | 4.27% | 4.27% | $53.63B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 3.05M | 4.07% | 4.07% | $51.13B | Nov 7, 2025 | ▼ 15.9K |
VR ADVISER, LLC pharmaceutical preparations | 2.69M | 3.58% | 3.58% | $45.01B | Nov 14, 2025 | — held |
BRAIDWELL LP pharmaceutical preparations | 2.58M | 3.44% | 3.44% | $43.21B | Nov 14, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 2.39M | 3.19% | 3.19% | $40.10B | Nov 13, 2025 | — held |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 2.06M | 2.75% | 2.75% | $34.53B | Nov 14, 2025 | ▼ 25.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
15
Increased
+2.16M shares3
New Positions
first time holders21
Decreased
−2.43M shares0
Sold Out
fully exitedNet shares change (top 50)
269.2K
+2.16M / −2.43M
Net new holders
-3
3 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SYRE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
12
Buy transactions
36
Sell transactions
0.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Sloan Sheldon Chief Medical Officer | Jun 3, 2026 | Sale | 8,333 | $75.00 | $625.0K | 0 | Form 4 ↗ |
Turtle Cameron Chief Executive Officer | Jun 1, 2026 | Sale | 3,557 | $69.40 | $246.9K | 609.0K | Form 4 ↗ |
Turtle Cameron Chief Executive Officer | Jun 1, 2026 | Sale | 8,149 | $70.50 | $574.5K | 600.8K | Form 4 ↗ |
Turtle Cameron Chief Executive Officer | Jun 1, 2026 | Sale | 3,294 | $71.38 | $235.1K | 597.5K | Form 4 ↗ |
Burrows Scott L Chief Financial Officer | Jun 1, 2026 | Sale | 1,801 | $69.75 | $125.6K | 103.7K | Form 4 ↗ |
Burrows Scott L Chief Financial Officer | Jun 1, 2026 | Sale | 2,599 | $70.77 | $183.9K | 101.1K | Form 4 ↗ |
Burrows Scott L Chief Financial Officer | Jun 1, 2026 | Sale | 3,100 | $72.06 | $223.4K | 98.0K | Form 4 ↗ |
Fairmount Funds Management LLC director | May 27, 2026 | Award | 8,026 | $72.51 | $582.0K | 8.0K | Form 4 ↗ |
Albers Jeffrey W. director | May 27, 2026 | Award | 8,026 | $72.51 | $582.0K | 8.0K | Form 4 ↗ |
HENDERSON MICHAEL THOMAS director | May 27, 2026 | Award | 8,026 | $72.51 | $582.0K | 8.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Spyre Therapeutics, Inc. (SYRE) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 12.96%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Spyre Therapeutics, Inc. is FMR LLC, holding approximately 9.06 million shares — equal to 12.09% of outstanding shares — as of September 30, 2025.
A total of 138 institutional investors currently hold SYRE stock, with a combined institutional value of approximately $1.08 billion as of the most recent 13F filing period.
Frequently asked questions
SYRE ownershipSpyre Therapeutics, Inc. (SYRE) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is FMR LLC with a 12.09% stake. Company insiders hold 12.96%. Data sourced from SEC Form 13F as of September 30, 2025.